738 results on '"Barthelmes, Daniel"'
Search Results
2. Effects of hydroxychloroquine therapy on choroidal volume and choroidal vascularity index
3. One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry
4. Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
5. RAPID ONSET HYDROXYCHLOROQUINE TOXICITY
6. The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma
7. Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!
8. Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness!
9. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry
10. Dynamics and patterns of recurrence in neovascular AMD during real-world management using automated fluid monitoring
11. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration
12. Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
13. Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration
14. From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema
15. Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis
16. OUTCOMES OF SWITCHING FROM PROACTIVE TO REACTIVE TREATMENT AFTER DEVELOPING ADVANCED CENTRAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
17. Evaluation of Increase in Retinal Thickness as Diagnostic Marker in Central Artery Occlusion
18. Hunter Syndrome and Bullʼs Eye Maculopathy
19. One-year anti-VEGF therapy outcomes in diabetic macular edema based on treatment intensity: Data from the FRB! registry
20. Imaging Assessment of Peripapillary Vessel Diameters in Postmortem Eyes
21. Ophthalmological Outcomes in Patients with Susac Syndrome
22. Monoclonal Gammopathy of Ocular Significance – A Case Report
23. Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
24. Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry
25. Long-Term Prevalence of Fungal Keratitis at a Swiss Tertiary Eye Clinic.
26. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine.
27. Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries.
28. Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion
29. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence
30. Linear Interstitial Keratitis - Assessment of a Poorly Explored Clinical Entity
31. Pathogenesis of Choroidal Neovascularization
32. Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registry
33. Assessing PCR-Positive Acanthamoeba Keratitis—A Retrospective Chart Review.
34. A Novel Technique of Aseptic Manufacture of Autologous Serum Eye Drops (ASEDs) and Sterility Analysis of the Bottled Ophtioles.
35. Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study
36. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration
37. Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness!
38. A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
39. Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months
40. A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy: Fight Retinal Blindness! Cohort
41. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration
42. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine (FRB!)
43. Effects of hydroxychloroquine therapy on choroidal volume and choroidal vascularity index
44. Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries
45. Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-VEGF
46. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors
47. Outcomes in Neovascular Age-Related Macular Degeneration when Neovascular Lesion Activity Is Uncertain: Observational Study
48. Review of people with retinal vasculitis and positive QuantiFERON®-TB Gold test in an area nonendemic for tuberculosis
49. A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013–2016. The Fight Retinal Blindness! Project
50. FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.